1179 related articles for article (PubMed ID: 29415819)
21. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
[TBL] [Abstract][Full Text] [Related]
22. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Wanner C; Marx N
Diabetologia; 2018 Oct; 61(10):2134-2139. PubMed ID: 30132035
[TBL] [Abstract][Full Text] [Related]
23. Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.
Herat LY; Matthews J; Azzam O; Schlaich MP; Matthews VB
Curr Hypertens Rep; 2022 Mar; 24(3):67-74. PubMed ID: 35235172
[TBL] [Abstract][Full Text] [Related]
24. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
25. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Tikkanen I; Chilton R; Johansen OE
Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):81-6. PubMed ID: 26808705
[TBL] [Abstract][Full Text] [Related]
26. SGLT2 inhibitors: molecular design and potential differences in effect.
Isaji M
Kidney Int Suppl; 2011 Mar; (120):S14-9. PubMed ID: 21358697
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
Zelniker TA; Braunwald E
J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
[TBL] [Abstract][Full Text] [Related]
28. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
Tejedor Jorge A
Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
[TBL] [Abstract][Full Text] [Related]
29. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
O'Meara E; Verma S
Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
[TBL] [Abstract][Full Text] [Related]
30. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus.
Gill A; Gray SP; Jandeleit-Dahm KA; Watson AMD
Curr Diabetes Rev; 2019; 15(5):349-356. PubMed ID: 29663893
[TBL] [Abstract][Full Text] [Related]
31. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
[TBL] [Abstract][Full Text] [Related]
32. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
33. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation.
Sano M
Ther Adv Cardiovasc Dis; 2020; 14():1753944720939383. PubMed ID: 32715944
[TBL] [Abstract][Full Text] [Related]
34. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients.
AlKindi F; Al-Omary HL; Hussain Q; Al Hakim M; Chaaban A; Boobes Y
Transplant Proc; 2020; 52(1):175-178. PubMed ID: 31924404
[TBL] [Abstract][Full Text] [Related]
36. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Sakai K; Murohara T; Ajioka M
Geriatr Gerontol Int; 2018 Jan; 18(1):108-114. PubMed ID: 28861952
[TBL] [Abstract][Full Text] [Related]
37. [SGLT2 inhibitors for heart and kidney].
van der Giet M
Dtsch Med Wochenschr; 2023 Nov; 148(22):1456-1461. PubMed ID: 37918431
[TBL] [Abstract][Full Text] [Related]
38. Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves.
Katsurada K; Nandi SS; Sharma NM; Patel KP
Circ Heart Fail; 2021 Dec; 14(12):e008365. PubMed ID: 34789005
[TBL] [Abstract][Full Text] [Related]
39. Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.
Azzam O; Matthews VB; Schlaich MP
Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):135-141. PubMed ID: 35086983
[TBL] [Abstract][Full Text] [Related]
40. Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?
Sano M
Intern Med; 2020 Jan; 59(1):1-5. PubMed ID: 31178515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
